New York, NY (PRWEB) February 13, 2013
The prescription drug resource center DrugRisk.com is alerting women using the vaginal ring contraceptive NuvaRing of updated information on the site which shows sales of the device slowed for the last part of 2012 amid new safety warnings and an increase in patient injury claims.
“The goal of DrugRisk is to provide patients with updated information about drugs they are taking, allowing them to have informed discussions with their doctor and decide if they need legal advice. This includes the latest drug warnings, recalls, studies and litigation news,” explains DrugRisk representative Ryan Mayer.
The resource center previously added health expert warnings linking vaginal ring contraceptives like NuvaRing to higher risks of blood clots than traditional birth control pills. On June 14, 2012, the New England Journal of Medicine published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.*
Recently, DrugRisk also added a study from Brigham and Women’s Faulkner Hospital which found that combined hormone vaginal ring contraceptives like NuvaRing can increase blood clot risks for all women, but especially those suffering migraines.**
Now, the resource center has uncovered the latest financial statements from the maker of NuvaRing, Merck, which show that sales of the device slowed from $168 million to $164 million for the fourth quarter of 2012, a drop of over 2% from the previous year.***
DrugRisk has also learned that, due to the number of patients filing a NuvaRing lawsuit, cases have been consolidated to a special federal court in Missouri. The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri. New information on the site also shows claims have risen nearly 5% in recent months.****
Anyone who suffered blood clots, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.
Due to the specialized nature of federal MDL drug injury cases, the DrugRisk Center only recommends lawyers and law firms who have already handled NuvaRing lawsuits.
For more information on the research, side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.